Geisler, K <br/><br/>
Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model.  [electronic resource] 

 -  Oncology reports  May 2014 
 - 2015-20 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1791-2431 
<br/><br/><label>Standard No.: </label>10.3892/or.2014.3070  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>B-Lymphocytes--immunology<br/>Benzamides--therapeutic use<br/>DNA-Binding Proteins--genetics<br/>Drug Therapy, Combination<br/>Female<br/>Imatinib Mesylate<br/>Interferon-gamma--biosynthesis<br/>Interleukin-2--therapeutic use<br/>Killer Cells, Natural--immunology<br/>Lung Neoplasms--drug therapy<br/>Melanoma, Experimental--drug therapy<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Piperazines--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Skin Neoplasms--drug therapy<br/>T-Lymphocytes--immunology<br/>Tumor Necrosis Factor Receptor Superfamily, Member 7--biosynthesis